Moderna
MRNA
1,071 hedge funds and large institutions have $44.5B invested in Moderna in 2022 Q4 according to their latest regulatory filings, with 247 funds opening new positions, 301 increasing their positions, 365 reducing their positions, and 72 closing their positions.
243% more first-time investments, than exits
New positions opened: 247 | Existing positions closed: 72
74% more funds holding in top 10
Funds holding in top 10: 19 → 33 (+14)
53% more capital invested
Capital invested by funds: $29.1B → $44.5B (+$15.4B)
17% more funds holding
Funds holding: 915 → 1,071 (+156)
1.49% more ownership
Funds ownership: 63.19% → 64.69% (+1.5%)
10% more call options, than puts
Call options by funds: $3.7B | Put options by funds: $3.37B
18% less repeat investments, than reductions
Existing positions increased: 301 | Existing positions reduced: 365
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$327M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$253M |
| 3 |
Goldman Sachs
New York
|
+$244M |
| 4 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
+$221M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$147M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$607M |
| 2 |
Renaissance Technologies
New York
|
-$149M |
| 3 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$111M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$80.7M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$77.2M |
MRNA Hedge Fund Activity: Q4 2022 in Review
1,071 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Moderna (MRNA) for Q4 2022, worth a combined $44.5B — up 53% from $29.1B a quarter earlier.
Buyers outnumbered sellers: 247 funds opened new MRNA positions and 72 closed out — a net gain of 175 holders — while 301 added to existing stakes and 365 trimmed.
The largest buyer was Capital World Investors, adding an estimated $327M. The largest seller was T. Rowe Price Associates, cutting an estimated $607M.
- 1,071 institutional investors held Moderna (MRNA) as of Q4 2022, up from 915 in Q3 2022.
- Funds reported $44.5B of Moderna stock for Q4 2022, up 53% quarter-over-quarter.
- 247 funds opened new Moderna positions in Q4 2022 and 72 closed out, a net change of +175 holders.
- The largest Moderna buyer in Q4 2022 was Capital World Investors, an estimated $327M added.
- The largest Moderna seller in Q4 2022 was T. Rowe Price Associates, an estimated $607M sold.
Based on aggregated 13F filings for Q4 2022.